Clinical review: Lessons learned from the hGH era
- PMID: 21865374
- DOI: 10.1210/jc.2011-1739
Clinical review: Lessons learned from the hGH era
Abstract
Today, many medical interventions that begin as treatments for disease often expand into therapies that reduce disability, lessen disadvantage, or even confer advantage. Forces that propel profitable drugs, devices, and procedures dominate over considerations of efficient and equitable distribution of resources. This dominance is fueled by industry-physician collaborations often biased by prior assumptions, reliant on surrogate outcomes, and advantageous to marketing. Interventions are justified by "medicalization" of physiologic variations (e.g. short stature) as defects or disease, and nudged into "standard practice" by key opinion leaders. The story below of recombinant human growth hormone (hGH) treatment of short stature is one vivid example, but others (e.g. expansion of drug treatment to "optimize" cholesterol profiles, bone health, psychological well-being) can be found throughout medicine. In the new obesity era, lessons learned from the hGH era will be needed to keep the field of pediatric endocrinology empowered to make the key clinical decisions, and free of unintended consequences for patients and runaway health care inflation for society.
Similar articles
-
Short stature and its treatment in Turner and Noonan syndromes.Curr Opin Endocrinol Diabetes Obes. 2012 Feb;19(1):40-6. doi: 10.1097/MED.0b013e32834ed64e. Curr Opin Endocrinol Diabetes Obes. 2012. PMID: 22157403 Review.
-
Use and abuse of human growth hormone.Annu Rev Med. 1994;45:407-20. doi: 10.1146/annurev.med.45.1.407. Annu Rev Med. 1994. PMID: 8198391 Review.
-
Human growth hormone therapy of non-growth hormone deficient children.Pediatrician. 1987;14(3):178-82. Pediatrician. 1987. PMID: 3331012 Review.
-
Growth hormone (GH) treatment in short normal children: absence of influence of time of injection and resistance to GH autofeedback.J Clin Endocrinol Metab. 1991 Dec;73(6):1269-75. doi: 10.1210/jcem-73-6-1269. J Clin Endocrinol Metab. 1991. PMID: 1955508 Clinical Trial.
-
Growth hormone therapy in achondroplasia.Am J Med Genet. 1992 Mar 1;42(5):667-70. doi: 10.1002/ajmg.1320420508. Am J Med Genet. 1992. PMID: 1632435
Cited by
-
Growth Hormone Treatment for Non-GHD Disorders: Excitement Tempered by Biology.J Clin Endocrinol Metab. 2024 Jan 18;109(2):e442-e454. doi: 10.1210/clinem/dgad417. J Clin Endocrinol Metab. 2024. PMID: 37450564 Free PMC article. Review.
-
Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding.Minerva Pediatr. 2020 Jun;72(3):206-225. doi: 10.23736/S0026-4946.20.05821-1. Epub 2020 Apr 9. Minerva Pediatr. 2020. PMID: 32274914 Free PMC article. Review.
-
A Retrospective Analysis of Patients with Short Stature in the South of China between 2007 and 2015.Biomed Res Int. 2018 Dec 20;2018:5732694. doi: 10.1155/2018/5732694. eCollection 2018. Biomed Res Int. 2018. PMID: 30671461 Free PMC article.
-
WHO and national lists of essential medicines in Mexico, Central and South America, and the Caribbean: are they adequate to promote paediatric endocrinology and diabetes care?BMJ Glob Health. 2016 Oct 27;1(3):e000114. doi: 10.1136/bmjgh-2016-000114. eCollection 2016. BMJ Glob Health. 2016. PMID: 28588968 Free PMC article.
-
Treatment of children and adolescents with idiopathic short stature.Nat Rev Endocrinol. 2013 Jun;9(6):325-34. doi: 10.1038/nrendo.2013.71. Epub 2013 Apr 23. Nat Rev Endocrinol. 2013. PMID: 23609338 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
